CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007
October 11 2007 - 4:01PM
PR Newswire (US)
PALO ALTO, Calif., Oct. 11 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) today announced that it will
release third quarter financial results for 2007 after the market
closes on Tuesday, November 6, 2007. Company management will
webcast a conference call at 4:30 p.m. EST, 1:30 p.m. PST, on the
company's website. To access the live webcast, please log on to the
Company's website at http://www.cvt.com/ and go to the Investor
Information section. Alternatively, domestic callers may
participate in the conference call by dialing (866) 524-6247, and
international callers may participate in the conference call by
dialing (706) 679-3061. Webcast and telephone replays of the
conference call will be available approximately two hours after the
completion of the call through Tuesday, November 13, 2007. Domestic
callers can access the replay by dialing (800) 642-1687, and
international callers can access the replay by dialing (706)
645-9291; the PIN access number is 20300373. About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology
to the discovery, development and commercialization of novel, small
molecule drugs for the treatment of cardiovascular diseases. CV
Therapeutics' approved product, Ranexa(R) (ranolazine
extended-release tablets), is indicated for the treatment of
chronic angina in patients who have not achieved an adequate
response with other antianginal drugs, and should be used in
combination with amlodipine, beta-blockers or nitrates. CV
Therapeutics also has other clinical and preclinical drug
development candidates and programs, including regadenoson, which
is being developed for potential use as a pharmacologic stress
agent in myocardial perfusion imaging studies, and CVT-6883, which
is being developed as a potential treatment for asthma and other
conditions. These product candidates have not been determined by
any regulatory authorities to be safe or effective in humans for
any use. Complete prescribing information for Ranexa, including
detailed safety and dosage information are available at
http://www.ranexa.com/. DATASOURCE: CV Therapeutics, Inc. CONTACT:
Investors and Media, John Bluth, Executive Director, Corporate
Communications and Investor Relations of CV Therapeutics, Inc.,
+1-650-384-8850 Web site: http://www.cvt.com/
http://www.ranexa.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024